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ABSTRACT
Prostate cancer (PCa) is a leading cause of male cancer-related deaths. A 
significant fraction of prostate tumors are very aggressive, often metastasizing to 
bone, causing significant morbidity and mortality. Also, PCa is associated with high 
rates of recurrence, often attributed to the existence of cancer stem cells. Epithelial-
mesenchymal transition (EMT), a process characterized by decreased expression of 
epithelial genes and increased expression of mesenchymal genes, plays a critical 
role in tumor invasion, metastasis and recurrence. In PCa, EMT has been implicated 
particularly in the context of metastatic disease and microRNAs have emerged as 
critical post-transcriptional regulators of PCa EMT. In this review, we summarize the 
role of miRNAs in PCa EMT that play a role in progression, metastasis and recurrence. 
Studies till date suggest that microRNAs mediate efficient and reversible control of 
PCa EMT via multiple mechanisms including either by (i) directly repressing single 
or multiple EMT-TFs or regulating cytoskeletal components (epithelial/mesenchymal 
genes) or (ii) regulating key signaling pathways involved in EMT. Oncogenic 
microRNAs often act as EMT promoters by repressing epithelial characteristics and 
tumor suppressive miRNAs act by inhibiting mesenchymal progression. Further, 
EMT is mechanistically linked to stem cell signatures in PCa and several miRNAs 
implicated in EMT have been reported to influence PCa stem cells. Loss of EMT-
inhibiting miRNAs and/or gain of EMT promoting miRNAs lead to induction of PCa 
EMT, leading to tumor progression, metastasis and recurrence. Restoring expression 
of tumor suppressive miRNAs and inhibiting oncogenic miRNAs represent potential 
therapeutic opportunities to prevent disease metastasis and recurrence.
INTRODUCTION
Prostate cancer (PCa) is the most commonly 
diagnosed cancer among men [1, 2]. It is the second 
leading cause of male cancer-related deaths in US with 
an estimated 26,120 deaths in 2016 [3]. Prostate tumors 
are often indolent [4] but a significant fraction of tumors 
are very aggressive, often metastasizing to bone and 
other organs, causing significant morbidity and mortality 
[5]. PSA (prostate-specific antigen) screening has 
revolutionized the clinical management of prostate cancer 
[6]. However, owing to the drawbacks of PSA including 
low specificity and inability to differentiate between 
indolent and aggressive prostate tumors, prostate cancer 
clinical management is often challenging. Treatment 
options for advanced metastatic disease are limited 
and cause marginal increases in survival [7, 8] Also, 
PCa is associated with high rates of disease recurrence, 
with ~40% of localized PCa cases having relapse after 
initial therapy [9] and tumor progression to a hormone 
refractory/castration resistant stage [1, 10] that is 
essentially untreatable [1, 11]. A major challenge is the 
elucidation of underlying molecular pathways of PCa 
progression, recurrence and metastasis that will open new 
avenues for the design of effective diagnostic, prognostic 
and therapeutic strategies for better clinical management 
of the disease.
Epithelial cancer cells convert to motile, 
mesenchymal cells by undergoing an epithelial-
                  Review
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mesenchymal transition (EMT) [12-14] that plays a 
critical role in cancer metastasis and tumor invasion. 
EMT is characterized by changes in gene expression 
profile, including decreased expression of epithelial genes, 
such as E-cadherin (also known as cadherin 1 [CDH1], 
and increased expression of mesenchymal genes, such as 
N-cadherin and vimentin. The EMT process is a complex 
genetic program that involves complex interactions 
of diverse inducers [e.g. Transforming Growth Factor 
β (TGFβ), Fibroblast Growth Factor (FGF), multiple 
signaling pathways (e.g. Wnt signaling) and is coordinated 
in a large part by several EMT-transcription factors (TF). 
EMT and its reverse process, mesenchymal-epithelial 
transition (MET), play a critical role during organogenesis 
and tissue differentiation during normal embryonic 
development [14-17]. These embryonic processes are 
reactivated by primary tumor cells to acquire motility, 
invasiveness and form secondary tumors at distant sites. 
Following EMT, cells detach from the primary tumor, 
circulate through blood or lymphatic routes, and colonize 
a distant site wherein the cells undergo MET to revert back 
to their immobile epithelial states, leading to development 
of secondary tumors after metastasis [16]. It has been 
proven that the loss of the epithelial marker, E-cadherin 
(E-cad/CDH1), is a causal factor in cancer progression 
[18]. EMT promotes stem cell properties endowing cancer 
cells with the capabilities of continued self-renewal [19].
Several EMT-transcription factors (EMT-TFs) 
repress the expression of E-cad and other epithelial markers 
and induce the expression of mesenchymal markers [16]. 
There are three major families of transcription factors that 
control EMT - Zeb (Zeb1/Zeb2); zinc finger Snail (Snail/
Slug); and basic helix-loop-helix families (e.g. Twist1) 
[16]. The Snail and Zeb family of transcription factors are 
highly conserved zinc finger transcription repressors that 
bind to E-box like promoter elements in DNA, thereby 
influencing gene expression and tumorigenesis. Zeb1 
and Zeb2 have been shown to regulate the expression of 
various EMT- and tumor related genes and thereby have 
been implicated in EMT, tumorigenesis and metastasis 
[20-24]. It is now well established that EMT-TFs play 
important roles in tumorigenesis. Snai1, Snai2, Zeb1, 
Zeb2 and Twist expression have been correlated with 
increased metastasis and poor prognosis in human tumors 
[25]. In addition, epigenetic mechanisms also play a role 
in EMT and epigenetic regulators like Bmi1 promote 
EMT [26]. Several signaling pathways regulate EMT 
and include key molecules such as TGFβ (transforming 
growth factor beta), fibroblast growth factor receptors 
(FGFRs) and platelet-derived growth factor (PDGF) [18]. 
TGFβ is a well-known inducer of EMT [15, 16, 18] that 
works by targeting the EMT-TFs through Smad-dependent 
and -independent transcriptional pathways [15]. Other 
soluble growth factors that have been shown to induce 
EMT include EGF, IGF1, and β2-microglobulin [15]. In 
addition, TGFβ cross-talks with signaling pathways such 
as Wnt, Notch, NF-κB and Receptor Tyrosine Kinases 
(RTKs) to induce EMT. Signaling via RTKs and their 
downstream effectors such as PI3K, MAPK is crucial to 
regulate EMT [18].
MicroRNAs recently emerged as important 
regulators of EMT and MET in various cancers [16, 
18]. MicroRNAs (miRNAs) are small, noncoding RNAs 
that suppress gene expression post transcriptionally via 
sequence-specific interactions with the 3’- untranslated 
regions (UTRs) of cognate mRNA targets [27]. 
miRNAs suppresses their cognate target genes through 
the destabilization or cleavage of the mRNA and/or 
translational inhibition [14, 16]. A single miRNA can 
target many mRNAs, and conversely, many miRNAs can 
target a single mRNA [16]. MicroRNAs regulate EMT 
through their ability to post-transcriptionally regulate 
various components of the process such as EMT-TFs, 
epithelial and mesenchymal genes or by regulating key 
signaling pathways [14, 16, 18]. A role for miRNAs that 
affects EMT and progression and metastasis of human 
cancers is increasingly emerging [25, 28, 29]. In prostate 
cancer, the role of miRNAs in EMT is being explored 
and there are few reports. Here we review and summarize 
the role of miRNAs in prostate cancer EMT that play a 
role in prostate cancer progression, metastasis and tumor 
recurrence. 
PROMINENT MICRORNAS REGULATING EMT 
IN VARIOUS CANCERS
miRNAs have been estimated to target over one-
third of the human genome [14, 18]. In view of the 
enormous regulatory potential of miRNAs, deregulated 
miRNA expression has been revealed in various disease 
states, including cancer [30, 31]. miRNAs can be 
oncogenic or tumor-suppressive [32]. In addition, several 
miRNAs called ‘metastamirs’ influence tumor metastasis 
[14]. miRNAs affect EMT and MET and thereby regulate 
progression and metastasis of various human cancers [25, 
28, 29]. Prominent examples are the miR-200 family and 
miR-205 that regulates EMT through direct targeting 
of Zeb1 and Zeb2 [25, 33, 34]. miR-9, MYC/MYCN-
induced miRNA, directly targets E-cadherin and breast 
cancer metastasis [35]. miR-103/107 induces EMT by 
downregulating miR-200 levels, and promotes metastatic 
dissemination of otherwise non-aggressive breast cancer 
cells in vivo [36]. miR-30a inhibits EMT by directly 
targeting Snai1 in non-small cell lung cancer cells [37]. 
Treatment of mammary epithelial cells with TGFβ induced 
miR-155, whose knockdown suppressed TGFβ-induced 
EMT, migration, and invasion through direct targeting of 
RhoA [38]. miR-204 plays a critical role in maintaining 
epithelial barrier function and cell physiology by 
directly targeting TGFβR2 and Snail2 in retinal pigment 
epithelium [39]. The miR-221/222 miRNA cluster has 
been found to induce EMT in breast cancer cells [40]. 
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miR-27 is upregulated in gastric cancer metastasis and 
enhances EMT through regulation of Zeb1, Zeb2 and Slug 
[41]. These studies support a crucial role of microRNAs in 
controlling EMT and metastasis. 
EMT IN PROSTATE CANCER
In prostate cancer, EMT has been implicated 
particularly in the context of metastatic disease [26, 
42-44]. E-cadherin expression is commonly lost or 
reduced in PCa [26, 42]. Loss of E-cadherin and gain of 
mesenchymal marker, N-cadherin has been associated 
with multiple end points of progression and cancer 
related mortality [20-24]. Also, PB-Cre4Ptenfl/flTP53fl/
fl mouse model of prostate cancer demonstrate the role 
of EMT in development of aggressiveness. These mice 
represent prostatic intraepithelial neoplasia (PIN) at 
8 weeks, adenocarcinoma formation by 4 months and 
the progressive development of EMT and sarcomatoid 
carcinoma with mesenchymal stem cell characteristics, 
leading to the death of most animals at about 7 months 
of age [45, 46]. Also, sarcomatoid carcinomas with a 
metastatic propensity have been described in humans with 
prostatic disease [47] supporting the existence of EMT 
like states in prostate cancer. Benign prostatic hyperplasia 
(BPH) of the prostate exhibits manifestations of EMT state 
characterized by accumulation of mesenchymal-like cells 
derived from the prostatic epithelium and endothelium 
[48]. TGFβ acts as a tumor suppressor in non-tumorigenic 
prostate epithelial cells, but promotes EMT in tumorigenic 
prostate cells [49]. In prostate cancer, TGFβ levels have 
been reported to increase with tumor burden and PCa 
metastases, also increasing in circulation [50, 51] and are 
negatively correlated with prognosis. ZEB1 is also a direct 
repressor of E cadherin in prostate cancer cell lines, and its 
level of expression correlates with Gleason score [44,45]. 
The Wnt signaling pathway has also been implicated in 
EMT-like states in prostate cancer [26]. 
MICRORNAS AND EMT IN PROSTATE CANCER
Studies point to an important role of microRNAs 
in regulating EMT and MET in prostate cancer, that in 
turn regulates tumor progression and metastasis (Table 1). 
MicroRNAs control EMT and MET through efficiently 
targeting single or multiple components that impinge 
upon these regulatory pathways via multiple mechanisms- 
either by (i) directly repressing single or multiple EMT-
TFs or regulating cytoskeletal components (epithelial 
and mesenchymal genes) (Figure 1) or (ii) by regulating 
key signaling pathways involved in EMT [14, 16, 18]. 
(Figure 2) Thus, miRNAs impact these pathways in 
various regulatory modes and their regulation is often 
controlled by double-negative feedback loops, leading to 
an efficient and flexible control of EMT. Dysregulation 
of miRNAs leads to induction of EMT states, leading 
to tumor progression, recurrence and metastasis. Tumor 
suppressive miRNAs act by inhibiting EMT and oncogenic 
microRNAs often act as EMT promoters. The following 
sections highlight the significant studies on suppressive/
oncogenic microRNAs in PCa that act by regulating EMT. 
An understanding of the role of miRNA-mediated EMT 
Figure 1: MicroRNAs regulating EMT-TFs in prostate cancer. Schematic illustration depicting microRNAs that have been 
reported to regulate major families of EMT- transcription factors (Zeb, Snail and Twist) in prostate cancer. MicroRNAs mediate PCa EMT 
by directly repressing single or multiple EMT-TFs.  EMT-inhibiting miRNAs,  EMT-promoting miRNAs, solid bars denote 
transcriptional repression, solid arrows denote transcriptional activation. As indicated, microRNAs inhibit EMT by directly or indirectly 
repressing Zeb1/2, Twist, and/or Snai1/2. miR-200, miR-145, miR-203, miR-205 repress ZEB1/2; miR-1 and miR-186 inhibit TWIST; 
miR-1 and miR-124 repress SNAI2; let-7 and miR-154 inhibit EMT by targeting HMGA2. Conversely, miR-301a represses p63 which 
downregulates miR-205 causing an upregulation of Zeb1/2. In addition, some of the depicted miRNAs participate in double-negative 
feedback loops with their respective targets as represented for miR-200, miR-145 and miR-1. 
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program may help elucidate the mechanistic model of PCa 
progression and metastasis and identify novel targets for 
therapeutic intervention.
MicroRNAs that inhibit EMT
Several tumor suppressive miRNAs act to inhibit 
PCa EMT by directly repressing one or more EMT-TFs 
or inhibiting signaling pathway components influencing 
EMT. These miRNAs negatively regulate tumor 
progression and metastasis as EMT is considered as the 
Table 1: MicroRNAs regulating EMT in prostate cancer
MicroRNA Effects on EMT Target(s) References
miRNAs primarily targeting 
EMT transcription factors 
or cytoskeletal components
miR-1 Inhibit Slug, Twist1 [55, 58]
miR-124 Inhibit Slug [70]
miR-145 Inhibit ZEB2, HEF1 [67, 68]
miR-200 Inhibit Zeb1, Zeb2, Slug [52]
miR-203 Inhibit
Zeb2, Bmi1, Survivin 
CKAP2, LASP1, WASF1, 
ASAP1 mRNAs
[62, 63]
miR-205 Inhibit Zeb2, Protein Kinase Cε [60]
miR-186 Inhibit Twist1 [71]
miR-23a-3p Promote E-cadherin [105]
miRNAs targeting signaling 
pathways implicated in 
EMT
let 7 family Inhibit HMGA2 [82]
miR-21 Promote BTG2, TGFβ [106, 110]
miR-23b Inhibit Src kinase and Akt [91]
miR-29b Inhibit MMP2 [95]
miR-30 Inhibit ERG [92]
miR-32 Promote BTG2 [108]
miR-34a Inhibit LEF1 [89]
miR-34b Inhibit Akt [90]
miR-100 Inhibit AGO2 [93]
miR-154 Inhibit HMGA2 [85]
miR-154* Promote SMAD7 [112]
miR-195 Inhibit FGF2, HMGA1, RPS6KB [97-99]
miR-223 Inhibit ITGA3, ITGB1 [100]
miR-301a Promote p63 [104]
miR-331-3p Promote NRP2, NACC1 [114]
miR-379 Promote FOXF2 [112]
miR-573 Inhibit FGFR1 [102]
miRNAs affecting EMT and 
PCa stem cells
miR-200 Inhibit Notch1 [80]
Let-7 Inhibit EZH2 [80, 125]
miR-205 Inhibit Zeb2, Protein Kinase Cε [60]
miR-145 Inhibit Zeb2 [67]
miR-21 Promote [124]
Table summarizes the miRNAs that have been reported to inhibit/promote EMT in prostate cancer. Target genes of the 
respective miRNAs are indicated in column 3.
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initiating and most critical step in invasion and metastasis 
[13]. 
EMT-inhibiting miRNAs primarily regulating EMT-
TFs 
MicroRNAs such as miR-200 family, miR-205 and 
miR-203 promote the epithelial state and inhibit EMT by 
primarily repressing EMT-TFs among other targets (Figure 
1 and Table 1). Loss of these miRNAs leads to induction 
of EMT states as highlighted below:
miR-200 family and miR-1
The miR-200 family includes miR-200a, miR-
200b, miR-200c, miR-141, and miR-429, all of which 
are significantly downregulated in PCa. Each of these 
miRNAs has been reported to suppress PCa metastasis 
via EMT inhibition. miR-200 inhibits Platelet-Derived 
Growth Factor-D (PDGF-D) induced EMT in PC3 cells by 
targeting and repressing Zeb1, Zeb2, and Slug expression 
(Figure 1) [52]. Similarly, miR-200b significantly 
inhibited tumor growth and cell proliferation in PC-3 cells 
due to inhibition of EMT [53]. Slabakova et al showed 
that miR-200 can counteract TGFβ1-induced EMT in 
benign prostate hyperplasia (BPH) cells [54]. Liu et al 
identified that miR-200 along with miR-1 act as negative 
regulators of EMT in Pten and TP53 null murine models 
[55]. miR-1 and miR-200 repress EMT by targeting Slug, 
which plays an important regulatory role in mesenchymal 
differentiation. Further, Slug was found as a direct 
repressor of miR-1 and miR-200 transcription suggesting 
that Slug and miR-1/miR-200 form a self-reinforcing 
regulatory loop that leads to EMT amplification (Figure 1) 
[55]. Also, transcription factor OVOL has been reported to 
induce miR-200 expression [56] and has been predicted to 
modulate PCa EMT by interacting with the miR-200/ZEB 
axis [57]. miR-1 targets Twist1 in PCa [55]. EGFR has 
been shown to act as a transcriptional repressor of miR-1 
leading to oncogenic activation of Twist1, contributing to 
accelerated PCa bone metastasis [58]. 
miR-205
miR-205 shows significantly lower expression 
levels in prostate cancer cells in comparison to normal 
prostate cells [59]. miR-205 overexpression in a prostate 
cancer cell line led to alterations consistent with MET 
and a reduction in cell invasion primarily through 
downregulation of protein kinase Cε [60]. In addition, 
miR-205 was shown to directly target Zeb2, N-chimaerin, 
ErbB3, E2F1 and E2F5 in prostate cancer cells [60]. 
Another study showed that miR-205 is essential for the 
inhibitory effects of p63 on PCa EMT markers, such as 
Zeb1, and metastasis (Figure 1) [61]. miR-205 expression 
in PCa was shown to be regulated by p63 (both TAp63 
and ΔNp63 isoforms). ΔNp63 or miR-205 significantly 
inhibited the incidence of lung metastasis in vivo in a 
mouse tail vein model. Further, in human PCa specimens, 
partial or complete loss of the ∆Np63/miR-205 axis was 
found to be correlated with EMT expression patterns and 
a predictor of metastatic behavior and poor prognosis [61]. 
Figure 2: MicroRNAs regulating major signaling pathways involved in EMT in prostate cancer. Schematic illustration 
depicting microRNAs that have been reported to regulate major signaling pathways involved in EMT in prostate cancer. These pathways 
include TGFβ signaling, Wnt signaling, PI3K/Akt/Src mTOR signaling, and Notch signaling. The key microRNAs regulating these 
pathways are indicated.  EMT-inhibiting miRNAs,  EMT-promoting miRNAs, solid bars denote transcriptional repression, 
solid arrows denote transcriptional activation. miR-21, miR-154* impinge upon TGFβ pathway; miR-379 and miR-34a promote and inhibit 
Wnt signaling, respectively. miR-34b, miR-23b, miR-195 inhibit PI3K/Akt/Src/mTOR signaling and miR-200 inhibits Notch signaling.
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miR-203
miR-203 is a tumor suppressor miRNA that is 
downregulated in PCa [62, 63]. We provided first evidence 
that miR-203 represses EMT by directly targeting Zeb2 
(Figure 1) and other EMT regulators, including Bmi1, 
that in turn regulate invasion and metastasis of prostate 
cancer [26, 64]. In addition, miR-203 regulates a cohort 
of pro-metastatic genes including survivin and bone-
specific effectors including Runx2, a master regulator of 
bone metastasis [62, 63]. Upon overexpression in prostate 
cancer cell lines, miR-203 induces MET and inhibits cell 
invasion [62, 63]. Viticchie et al. demonstrated that miR-
203 additionally targets a series of metastasis-promoting 
genes, including CKAP2, LASP1, WASF1 and ASAP1 
mRNAs [63]. 
miR-143/miR-145
miR-143/miR-145 form a cluster and are both 
reported to be downregulated in metastatic PCa [65]. 
Peng et al identified that downregulation of miR-143 and 
miR-145 is associated with induction of EMT and PCa 
bone metastasis [66]. miR-145 is a strong EMT repressor 
that directly targets Zeb2 [67]. Further, Zeb2 directly 
targets miR-145, repressing its transcription, thereby 
forming a double-negative feedback loop that regulates 
EMT, stemness and PCa bone metastasis (Figure 1). 
Zeb2 expression was positively correlated with bone 
metastasis in PCa patients and negatively correlated 
with miR-145 expression in primary PCa samples [67]. 
Guo et al showed that a cytoplasmic scaffolding protein, 
human enhancer of filamentation 1 (HEF1; also known as 
NEDD9/Cas-L), is also a direct miR-145 target. miR-145 
and HEF1 expression levels were negatively correlated in 
primary prostate cancer and bone metastatic specimens 
[68]. Further, miR-145 expression is controlled by DNA 
hypermethylation and tumor suppressor p53 in PCa [65, 
69]. WT-p53 upregulates the expression of miR-145, 
thereby suppressing metastasis and EMT in PC3 prostate 
cancer cells and these effects could be reversed by anti-
miR-145. Thus, miR-145 plays at least a partial role in the 
EMT inhibitory effects of WT-p53 [69].
miR-124 
Qin et al found that transforming growth factor-α 
(TGF-α) promotes EMT through downregulation of miR-
124 in prostate cancer cell line. Overexpression of miR-
124 on the TGF-α treated PCa cells inhibited the EMT 
inducing effects of TGF-α and reduced cellular invasion. 
Further, the authors demonstrated that miR-124 directly 
targets Slug (Figure 1) [70].
miR-186
miR-186 has been reported to be downregulated 
in human PCa tissues, particularly in metastatic samples 
and metastatic prostate cancer cell line [71]. Low miR-
186 expression was found to be correlated with poor 
patient survival. miR-186 was found to inhibit EMT and 
PCa metastasis by directly targeting and downregulating 
Twist1 [71]. 
Let7 family
The let-7 family of miRNAs include let-7a, let-7b, 
let-7c, let-7d, let-7e, let-7f, let-7g, and let-7i [72], all of 
which are significantly downregulated in PCa, compared 
to benign tissues and act as tumor suppressors [32]. 
Lin28 is a highly conserved RNA-binding protein and 
an embryonic stem cell factor that blocks the processing 
of let-7 precursors into mature miRNAs [72-74]. Lin28 
is frequently overexpressed in primary human tumors 
[75] and promotes oncogenesis and proliferation of 
cancer cells, by repression of the let-7 family [76]. Let-
7 expression has been reported to be downregulated in 
localized PCa tissues relative to benign peripheral zone 
tissue [77, 78]. Loss of let-7 expression has been linked to 
the development of poorly differentiated and aggressive 
cancers [79]. The let-7 miRNAs are tumor suppressive 
and have been shown to target oncogenes such as Ras, 
Myc and genes involved in cell cycle regulation. These 
miRNAs thereby target oncogenes at various metastatic 
steps including EMT [17]. Kong et al. reported an 
important link between let-7 and miR-200 with EMT 
states in prostate cancer [52, 80]. One of the let-7 family’s 
target genes in EMT is high mobility group protein A 
(HMGA), a chromatin associated nonhistone protein 
[81] that has been implicated in EMT. HMGA2 is highly 
expressed in PCa, and upon let-7 inhibition, HMGA2 
was de-repressed [82]. Thualt et al have demonstrated 
that HMGA2 cooperates with Smad to regulate Snail1 
expression and to induce EMT in human hepatocarcinoma 
cells [83]. Therefore, these results suggest that let-7 could 
inhibit EMT in PCa by targeting HMGA2 [84] (Figure 1). 
miR-154
Similarly, miR-154 inhibits EMT in prostate cancer 
cells by directly targeting HMGA2 [85]. HMGA2 is 
mostly upregulated in PCa tissue samples as compared to 
normal. Overexpression of miR-154 inhibited EMT and 
reduced migratory and invasive capabilities of PCa cells 
in vitro concomitant with HMGA2 repression (Figure 1) 
[85]. 
MicroRNAs regulating key signaling pathways 
implicated in EMT 
MicroRNAs also impinge upon key signaling 
pathways involved in EMT including TGFβ, Wnt, PI3K/
Akt and Receptor Tyrosine Kinases (RTKs) to regulate 
EMT (Figure 2 and Table 1) [18] as summarized below:
miR-34a/b 
The miR-34 family of tumor suppressive miRNAs 
include miR-34a/b/c that are encoded by two different 
genes. miR-34a precursor is transcribed from chromosome 
1 while miR-34b and miR-34c precursors are co-
transcribed from a region on chromosome 11 [86]. miR-
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34 is an important component of the p53 network and is 
directly transactivated by p53 [86, 87]. miR-34 has been 
reported to target key genes that function in cell cycle, 
apoptosis, senescence, cell migration, and invasion [86]. In 
mice, prostate epithelium-specific inactivation of miR-34 
and p53 leads to early invasive adenocarcinomas and high-
grade prostatic intraepithelial neoplasia with expansion 
of the prostate stem cell compartment [88]. miR-34a 
has been reported to be significantly downregulated 
in human PCa specimens in contrast to benign prostate 
tissues [89]. Further, it has been demonstrated that miR-
34a regulates PCa EMT by directly repressing LEF1 
(lymphoid enhancer-binding factor-1), a transcription 
factor in the Wnt signaling pathway that plays a role in 
cell proliferation and invasion (Figure 2) [89]. We reported 
that miR-34b is tumor suppressive in PCa and is silenced 
through CpG hypermethylation [90]. Reconstitution of 
miR-34b inhibited cell proliferation/invasion and EMT 
by directly targeting Akt and its downstream proliferative 
genes [90]. 
miR-23b
miR-23b is a methylation-silenced tumor suppressor 
in prostate cancer that works by directly targeting 
proto oncogene Src kinase and Akt (Figure 2) [91]. 
Overexpression of miR-23b in prostate cancer cells led 
to a decrease in mesenchymal markers and an increase in 
epithelial markers suggesting that miR-23b inhibits EMT 
and promotes MET [91].
miR-30
In PCa, Ets-related gene (ERG) is a frequently 
overexpressed oncogene that is activated by fusion 
events between promoter sequences of the TMPRSS2 and 
coding sequences of ERG. Kao et al showed that ERG is 
a direct target of miR-30 [92]. miR-30 is underexpressed 
in prostate cancer specimens and its overexpression 
in prostate cancer cells suppressed EMT and inhibited 
cell migration and invasion [92]. Further, Src inhibitors 
upregulated miR-30 levels suggesting that TMPRSS2-
ERG gene fusions are regulated by Src via miR-30 [92]. 
miR-100
miR-100 negatively regulated EMT in PC3 and 
DU145 cells and its expression was negatively correlated 
with bone metastasis of prostate cancer patients [93]. 
Downregulation of miR-100 promoted prostate cancer 
metastasis by upregulating Argonaute 2 (AGO2), a core 
effector protein of the miRNA-induced silencing complex 
which facilitates EMT [93]. 
miR-29b
miR-29b is downregulated in PCa cells as compared 
to normal prostate epithelial cells, and its expression was 
further lowered in metastatic prostate cancer cells [94]. 
Upon miR-29b transfection in PC3 prostate cancer cells, 
E-cadherin was upregulated while N-cadherin, Twist, 
and Snail expression were downregulated [94]. Owing to 
its EMT-inhibiting effects, ectopic miR-29b expression 
suppressed PCa metastasis in a mouse model [94]. Matrix 
metallopeptidase-2 (MMP-2) has been identified as a miR-
29b target in prostate cancer cells [95]. Further, miR-29b 
has been shown to enhance the chemotherapeutic effects 
of cisplatin through its direct targeting of DNMT3B (DNA 
(Cytosine-5-)-Methyltransferase 3 Beta) and Akt3 (v-Akt 
Murine Thymoma Viral Oncogene Homolog 3) [96].
miR-195
miR-195 is downregulated in prostate cancer tissues 
and low miR-195 is significantly associated with high 
Gleason score, biochemical recurrence and metastasis [97, 
98]. Prostate cancer cases with low miR-195 expression 
had a shorter relapse-free survival (RFS) time [98]. miR-
195 overexpression in DU-145 and PC3 PCa cell lines led 
to EMT inhibition and reduced invasion and migration 
by directly targeting fibroblast growth factor 2 (FGF2) 
[98]. Also, miR-195 has been reported to directly repress 
HMGA1 in prostate cancer [99]. Another study identified 
Ribosomal protein S6 kinase, RPS6KB, an important 
component of mTOR signaling pathway as a novel direct 
miR-195 target (Figure 2) [97]. The latter study suggests 
that miR-195 loss upregulates RPS6KB1, leading to 
a decreased expression of E-cadherin and increased 
expression of MMP-9 and VEGF proteins that culminates 
in effects on tumor invasion, angiogenesis, EMT, and 
survival [97]. 
miR-223
miR-223 is significantly downregulated in PCa 
tissues and restoration of miR-223 led to inhibited cell 
proliferation/invasion [100]. miR-223 was shown to 
directly target integrin alpha 3 (ITGA3) and integrin 
β1 (ITGβ1) [100]. These integrins are involved in focal 
adhesion and extracellular matrix (ECM) receptor 
interactions that play a role in EMT induction in prostate 
cancer cells [64, 101]. 
miR-573
miR-573 is downregulated in metastatic PCa 
in comparison to primary PCa [102]. miR-573 
overexpression inhibited TGF-β1 induced EMT in vitro 
and lung metastasis in vivo by directly targeting the 
fibroblast growth factor receptor 1 (FGFR1) gene [102]. 
FGFR1 plays a critical role in prostate tumorigenesis, and 
miR-573 directly suppresses FGFR1 expression in PCa 
cells [102, 103]. Further, miR-573 was found to be directly 
regulated by transcription factor GATA3 suggesting 
the involvement of GATA3, miR-573 and FGFR1 in 
controlling PCa EMT [102].
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MicroRNA that promote EMT
In prostate cancer, various oncogenic microRNAs 
often repress epithelial characteristics or promote EMT as 
summarized below. 
EMT-promoting miRNAs regulating EMT-TFs or 
cytoskeletal components
Oncogenic miRNAs can promote EMT by 
augmenting the expression of EMT-TFs indirectly 
as exemplified by miR-301a or by directly targeting 
cytoskeletal components (epithelial genes). 
miR-301a
In a recent study, Nam et al showed that miR-301a 
induces EMT in prostate cancer cells by directly targeting 
and inhibiting the tumor suppressor p63. The loss of p63 
results in the downregulation of tumor suppressive miR-
205, causing upregulation of ZEB1 and ZEB2 (Fig.1), 
which in turn, suppresses E-cadherin [104].
miR-23a-3p
Wen et al. demonstrated that miR-23a-3p 
regulates TGF-β-induced EMT in androgen independent 
prostate cancer (AIPC) cell lines PC3 and Du145 [105]. 
Treatment of PCa cell lines with TGF-β led to miR-
23a-3p upregulation concomitant with E-cadherin 
downregulation. Further, miR-23a-3p was found to 
directly repress E-cadherin expression by binding to its 
3′UTR. Also, a bioactive coumarin derivative, osthole, 
suppressed EMT in vitro and metastasis in vivo by 
inhibiting miR-23a-3p expression and Snail signaling in 
AIPC cells [105].
EMT-promoting miRNAs regulating signaling 
pathways implicated in EMT
In addition, oncogenic miRNAs may repress 
tumor suppressor genes or act by repressing inhibitors 
of signaling pathways involved in EMT as summarized 
below (Table 1). 
miR-21
miR-21 is commonly upregulated in various cancers, 
including prostate cancer [106]. miR-21 has been reported 
to be Ras-induced, leading to tumor aggressiveness [107]. 
Overexpression of miR-21 in prostate cells promotes EMT 
leading to the transformation of normal prostate cells into 
prostate cancer cells [108] primarily from repression of 
B-cell translocation gene 2 (BTG2). B-cell translocation 
gene 2 (BTG2) is a basal protein that has been implicated 
in prostate cancer transformation and progression [108] 
and also possesses anti-proliferative activity [109]. 
A recent study shows that miR-21 overexpression 
concomitant with loss of the miR-15/16 cluster leads to 
aberrant TGFβ signaling, EMT, increased aggressiveness 
and PCa metastasis [110]. 
miR-32
Jalava et al showed that miR-32 also targets BTG2 
and that their expression levels are inversely correlated in 
castration-resistant prostate cancer (CRPC) [111]. miR-32 
is an androgen-regulated miRNA that is highly expressed 
in CPRC samples leading to reduced expression of BTG2 
[111]. 
miR-154* and miR-379
miR-154* and miR-379 are members of the delta-
like 1 homolog-deiodinase, iodothyroxine (DLK1-DIO3) 
cluster - a cluster that plays an important role in EMT and 
embryonic development. Gururajan et al demonstrated that 
both miR-154* and miR-379 have elevated expression in 
bone metastatic PCa cell lines and tissues and miR-379 
expression correlated with progression-free survival of 
PCa [112]. Overexpression of these miRNAs promoted 
EMT in PCa [112] while their inhibition resulted in EMT 
reversal and decreased invasive capacities of PCa cells 
[112]. Analyses of the potential target pathways showed 
that these miRNAs regulate oncogenic pathways that 
activate EMT such as E2F signaling, Ras pathway, WNT 
and TGFβ pathways. [112]. miR-154* targets SMAD7, an 
inhibitor of the TGFβ pathway [113] while miR-379 was 
predicted to inhibit forkhead box F2 (FOXF2), a WNT 
pathway inhibitor (Figure 2) [112]. 
miR-331-3p 
miR-331-3p expression promotes EMT as its 
overexpression in the PC3 cell line led to upregulation of 
mesenchymal markers such as vimentin and N-cadherin, 
and downregulation of epithelial markers such as 
E-cadherin and desmoplakin [114]. Further, the authors 
demonstrated that miR-331-3p- mediated EMT was due 
to direct targeting of Neuropilin 2 (NRP2) and Nucleus 
Accumbens-Associated Protein 1(NACC1) expression. 
miR-331 expression is elevated in PCa cases with 
high Gleason score and was shown to be controlled by 
Syndecan-1 [114]. 
miR-129-3p
miR-129-3p has been reported to be upregulated 
in metastatic PCa cells [115]. miR-129-3p was found to 
directly repress Centriolar Coiled-Coil Protein 110kDa 
(CP110), a centrosomal protein that is downregulated 
in metastatic PCa. Lack of CP110 inhibition led to 
excessive centrosome amplification accompanied by 
increased E-cadherin expression, deregulated F-actin 
cytoskeleton and decreased invasion and metastasis [115]. 
Though a direct correlation was observed between CP110 
expression, E-cadherin expression and PCa metastases, 
no significant correlation could be established between 
CP110 expression and the expression of EMT-related 
genes in clinical prostate cancer samples [115]. 
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EMT promoting miRNAs with undefined mechanisms 
miR-409
miR-409-3p/-5p expression is elevated in bone 
metastatic PCa cell lines and in PCa tissues with higher 
Gleason scores [116]. High miR-409-3p expression was 
found to be correlated with progression-free survival of 
PCa patients. Further, orthotopic delivery of miR-409-3p/-
5p in the murine prostate gland induced EMT and tumors 
expressing EMT and stemness markers. Inhibition of miR-
409-5p in the bone metastatic ARCaPM prostate cancer 
cell line led to decreased bone metastasis and increased 
survival in an experimental mouse model [116]. 
MicroRNAs, EMT and prostate cancer stem cells 
Prostate cancer recurrence and progression has been 
associated with the existence of prostate cancer stem cells 
(CSC) or tumor-initiating cells (TIC). These cells are 
refractory to current therapies [117] and are characterized 
by various cell surface markers [118-122] such as CD44, 
CD133, integrin α2β1 and stem-cell signature genes such 
as Sox2, Nanog and Oct4. EMT endows cancer cells with 
stem cell properties [19, 123]. It has been reported that 
EMT is mechanistically linked to stem cell signatures 
in prostate cancer [80]. Several miRNAs implicated in 
EMT have been reported to influence prostate cancer 
stem cells indirectly by regulating EMT-TFs or by 
influencing the signaling pathways that impinge upon 
both EMT and stemness such as TGFβ, MAP kinase and 
Wnt signaling pathways [19, 123]. Decreased expression 
of miR-200 and/or let-7 family has been reported in PCa 
cells that have undergone EMT and display stem cell- 
like features [80]. miR-200 reexpression led to reversal 
of EMT and inhibition of stem cell properties such as 
decreased prostasphere-forming ability and clonogenicity 
concomitant with reduced expression of Notch1 
and Lin28B [80]. Similarly, miR-205 reverses EMT 
progression and inhibits stem-cell properties of PCa cells 
through repression of its targets Zeb2 and protein kinase 
Cε [60]. miR-145 inhibits EMT and stem cell properties 
in PCa [67] via its regulation of Zeb2. miR-21 is involved 
in EMT, maintenance of CSCs and therapeutic resistance 
[124]. Downregulation of miR-21 led to repression of 
EpCAM, CD44 and VEGF [124]. Let-7 directly targets 
Enhancer of Zeste homolog 2 (EZH2) and thereby 
regulates PCa CSCs. Loss of let-7 during PCa progression 
leads to increased expression of EZH2, contributing to 
PCa aggressiveness [125]. In addition to influencing CSCs 
indirectly through EMT, miRNAs can also regulate CSCs 
via their ability to directly regulate CSC markers [123]. 
As an example, miR-34a directly represses CD44 thereby 
inhibiting PCa stem cells and metastasis [126-128]. We 
showed that miR-708 is a key negative regulator of the 
CD44(+) subpopulation of prostate cancer cells by directly 
regulating CD44 [129]. Also, miR-708 directly targets 
Akt2, a component of the PI3K/Akt pathway, with roles 
in tumor progression and CSCs [129].
CONCLUSIONS AND FUTURE PERSPECTIVES
In conclusion, the role of miRNAs in PCa EMT 
is emerging and warrants further investigation. Studies 
till date suggest that microRNAs mediate efficient and 
reversible post-transcriptional control of prostate cancer 
EMT via multiple mechanisms including direct targeting 
of EMT-TFs, affecting signaling pathway components 
controlling EMT or by directly modulating cytoskeletal 
components. Oncogenic microRNAs often act as EMT 
promoters by repressing epithelial characteristics and 
tumor suppressive miRNAs act by inhibiting mesenchymal 
progression. Loss of EMT-inhibiting miRNAs and/or 
gain of EMT promoting miRNAs lead to induction of 
PCa EMT, leading to tumor progression, metastasis and 
recurrence. Restoring expression of tumor suppressive 
miRNAs and inhibiting oncogenic miRNAs represent 
therapeutic opportunities to prevent PCa metastasis and 
recurrence. 
ACKNOWLEDGMENTS
We thank Dr. Roger Erickson for his support and 
assistance with preparation of the manuscript. 
CONFLICTS OF INTEREST 
The author declares that there are no conflicts of 
interest.
GRANT SUPPORT
The authors are supported by the National Cancer 
Institute at the National Institutes of Health (Grant 
Number RO1CA177984 to SS, RO1CA138642 to RD). 
REFERENCES
1. Barlow LJ, Shen MM. SnapShot: Prostate cancer. Cancer 
cell. 2013; 24: 400 e401.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: 
a cancer journal for clinicians. 2016; 66: 7-30.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: 
a cancer journal for clinicians. 2015; 65: 5-29.
4. Jaiswal S, Sarmad R, Arora S, Dasaraju R, Sarmad K. 
Prostate Cancer for the Internist. N Am J Med Sci. 2015; 7: 
429-435.
5. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. 
Pathogenesis and treatment of prostate cancer bone 
Oncotarget67606www.impactjournals.com/oncotarget
metastases: targeting the lethal phenotype. Journal of 
clinical oncology : official journal of the American Society 
of Clinical Oncology. 2005; 23: 8232-8241.
6. Cary KC, Cooperberg MR. Biomarkers in prostate cancer 
surveillance and screening: past, present, and future. 
Therapeutic advances in urology. 2013; 5: 318-329.
7. Fong MK, Hare R, Jarkowski A. A new era for castrate 
resistant prostate cancer: a treatment review and update. 
Journal of oncology pharmacy practice : official publication 
of the International Society of Oncology Pharmacy 
Practitioners. 2012; 18: 343-354.
8. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. 
Molecular Pathology and Prostate Cancer Therapeutics: 
From Biology to Bedside. The Journal of pathology. 2013.
9. Grubb RL, 3rd, Kibel AS. Prostate cancer: screening, 
diagnosis and management in 2007. Mo Med. 2007; 104: 
408-413; quiz 413-404.
10. Kasper S, Cookson MS. Mechanisms leading to the 
development of hormone-resistant prostate cancer. Urol 
Clin North Am. 2006; 33: 201-210, vii.
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, 
Chi KN, Oudard S, Theodore C, James ND, Turesson I, 
Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone 
or mitoxantrone plus prednisone for advanced prostate 
cancer. N Engl J Med. 2004; 351: 1502-1512.
12. Kalluri R, Weinberg RA. The basics of epithelial-
mesenchymal transition. The Journal of clinical 
investigation. 2009; 119: 1420-1428.
13. Thiery JP. Epithelial-mesenchymal transitions in tumour 
progression. Nature reviews Cancer. 2002; 2: 442-454.
14. Zhang J, Ma L. MicroRNA control of epithelial-
mesenchymal transition and metastasis. Cancer Metastasis 
Rev. 2012; 31: 653-662.
15. Kyprianou N. ASK-ing EMT not to spread cancer. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2010; 107: 2731-2732.
16. Lamouille S, Subramanyam D, Blelloch R, Derynck R. 
Regulation of epithelial-mesenchymal and mesenchymal-
epithelial transitions by microRNAs. Curr Opin Cell Biol. 
2013; 25: 200-207.
17. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis 
R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 
RAS is regulated by the let-7 microRNA family. Cell. 2005; 
120: 635-647.
18. Zaravinos A. The Regulatory Role of MicroRNAs in EMT 
and Cancer. J Oncol. 2015; 2015: 865816.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, et al. The epithelial-
mesenchymal transition generates cells with properties of 
stem cells. Cell. 2008; 133: 704-715.
20. Imamichi Y, Konig A, Gress T, Menke A. Collagen 
type I-induced Smad-interacting protein 1 expression 
downregulates E-cadherin in pancreatic cancer. Oncogene. 
2007; 26: 2381-2385.
21. Maeda G, Chiba T, Okazaki M, Satoh T, Taya Y, Aoba T, 
Kato K, Kawashiri S, Imai K. Expression of SIP1 in oral 
squamous cell carcinomas: implications for E-cadherin 
expression and tumor progression. International journal of 
oncology. 2005; 27: 1535-1541.
22. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, 
Merkel S, Jung A, Kirchner T, Brabletz T. A transient, 
EMT-linked loss of basement membranes indicates 
metastasis and poor survival in colorectal cancer. 
Gastroenterology. 2006; 131: 830-840.
23. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, 
Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, 
Kirchner T, Behrens J, Brabletz T. The transcriptional 
repressor ZEB1 promotes metastasis and loss of cell 
polarity in cancer. Cancer research. 2008; 68: 537-544.
24. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh 
M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK. 
The transcription factor ZEB1 is aberrantly expressed in 
aggressive uterine cancers. Cancer research. 2006; 66: 
3893-3902.
25. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall 
GJ. The role of microRNAs in metastasis and epithelial-
mesenchymal transition. Cellular and molecular life 
sciences : CMLS. 2009; 66: 1682-1699.
26. Nauseef JT, Henry MD. Epithelial-to-mesenchymal 
transition in prostate cancer: paradigm or puzzle? Nature 
reviews Urology. 2011; 8: 428-439.
27. Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell. 2009; 136: 215-233.
28. Kang Y, Massague J. Epithelial-mesenchymal transitions: 
twist in development and metastasis. Cell. 2004; 118: 277-
279.
29. Zhang J, Ma L. MicroRNA control of epithelial-
mesenchymal transition and metastasis. Cancer metastasis 
reviews. 2012.
30. Calin GA. MicroRNAs and cancer: what we know and what 
we still have to learn. Genome medicine. 2009; 1: 78.
31. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. 
Annual review of medicine. 2009; 60: 167-179.
32. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, 
Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung 
HJ, Evans CP, et al. MicroRNA let-7c is downregulated in 
prostate cancer and suppresses prostate cancer growth. PloS 
one. 2012; 7: e32832.
33. Gregory PA, Bracken CP, Bert AG, Goodall GJ. 
MicroRNAs as regulators of epithelial-mesenchymal 
transition. Cell Cycle. 2008; 7: 3112-3118.
34. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin 
A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 
The miR-200 family and miR-205 regulate epithelial to 
mesenchymal transition by targeting ZEB1 and SIP1. Nat 
Oncotarget67607www.impactjournals.com/oncotarget
Cell Biol. 2008; 10: 593-601.
35. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, 
Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, 
Westermann F, Speleman F, Vandesompele J, et al. miR-9, 
a MYC/MYCN-activated microRNA, regulates E-cadherin 
and cancer metastasis. Nature cell biology. 2010; 12: 247-
256.
36. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi 
M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, 
Parenti AR, Daidone MG, Bicciato S, et al. A MicroRNA 
targeting dicer for metastasis control. Cell. 2010; 141: 
1195-1207.
37. Kumarswamy R, Mudduluru G, Ceppi P, Muppala 
S, Kozlowski M, Niklinski J, Papotti M, Allgayer H. 
MicroRNA-30a inhibits epithelial-to-mesenchymal 
transition by targeting Snai1 and is downregulated in 
non-small cell lung cancer. International journal of cancer 
Journal international du cancer. 2012; 130: 2044-2053.
38. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, 
Cheng JQ. MicroRNA-155 is regulated by the transforming 
growth factor beta/Smad pathway and contributes to 
epithelial cell plasticity by targeting RhoA. Molecular and 
cellular biology. 2008; 28: 6773-6784.
39. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li 
R, Zhao J, Majerciak V, Gaur AB, Chen S, Miller SS. 
MicroRNA-204/211 alters epithelial physiology. FASEB 
journal : official publication of the Federation of American 
Societies for Experimental Biology. 2010; 24: 1552-1571.
40. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O’Brien 
C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman 
RJ, Yue P, Bourgon R, et al. miR-221/222 targeting of 
trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-
mesenchymal transition in breast cancer. Science signaling. 
2011; 4: pt5.
41. Zhang Z, Liu S, Shi R, Zhao G. miR-27 promotes human 
gastric cancer cell metastasis by inducing epithelial-to-
mesenchymal transition. Cancer genetics. 2011; 204: 486-
491.
42. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow 
TG. Expression of E-cadherin in primary and metastatic 
prostate cancer. The American journal of pathology. 1996; 
148: 1375-1380.
43. Sethi S, Macoska J, Chen W, Sarkar FH. Molecular 
signature of epithelial-mesenchymal transition (EMT) in 
human prostate cancer bone metastasis. American journal 
of translational research. 2010; 3: 90-99.
44. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger 
P, Reiter RE, Ferriere JM. The epithelial-mesenchymal 
transition-inducing factor TWIST is an attractive target in 
advanced and/or metastatic bladder and prostate cancers. 
Urologic oncology. 2010; 28: 473-479.
45. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, 
Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman 
H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT 
via Slug-dependent and tumorigenesis via Slug-independent 
mechanisms. Oncogene. 2012.
46. Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng 
V, Camacho D, Simpson RM, Kelly K. Prostate epithelial 
Pten/TP53 loss leads to transformation of multipotential 
progenitors and epithelial to mesenchymal transition. The 
American journal of pathology. 2011; 179: 422-435.
47. Hansel DE, Epstein JI. Sarcomatoid carcinoma of the 
prostate: a study of 42 cases. The American journal of 
surgical pathology. 2006; 30: 1316-1321.
48. Alonso-Magdalena P, Brossner C, Reiner A, Cheng 
G, Sugiyama N, Warner M, Gustafsson JA. A role for 
epithelial-mesenchymal transition in the etiology of benign 
prostatic hyperplasia. Proceedings of the National Academy 
of Sciences of the United States of America. 2009; 106: 
2859-2863.
49. Ao M, Williams K, Bhowmick NA, Hayward SW. 
Transforming growth factor-beta promotes invasion in 
tumorigenic but not in nontumorigenic human prostatic 
epithelial cells. Cancer Res. 2006; 66: 8007-8016.
50. Adler HL, McCurdy MA, Kattan MW, Timme TL, 
Scardino PT, Thompson TC. Elevated levels of circulating 
interleukin-6 and transforming growth factor-beta1 in 
patients with metastatic prostatic carcinoma. The Journal 
of urology. 1999; 161: 182-187.
51. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, 
Bergh A. Transforming growth factor beta1 is associated 
with angiogenesis, metastasis, and poor clinical outcome in 
prostate cancer. The Prostate. 1998; 37: 19-29.
52. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim 
HR, Sarkar FH. miR-200 regulates PDGF-D-mediated 
epithelial-mesenchymal transition, adhesion, and invasion 
of prostate cancer cells. Stem Cells. 2009; 27: 1712-1721.
53. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-
200b inhibits prostate cancer EMT, growth and metastasis. 
PloS one. 2013; 8: e83991.
54. Slabakova E, Pernicova Z, Slavickova E, Starsichova A, 
Kozubik A, Soucek K. TGF-beta1-induced EMT of non-
transformed prostate hyperplasia cells is characterized by 
early induction of SNAI2/Slug. The Prostate. 2011; 71: 
1332-1343.
55. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, 
Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman 
H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT 
via Slug-dependent and tumorigenesis via Slug-independent 
mechanisms. Oncogene. 2013; 32: 296-306.
56. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller 
D, Sud S, Schumann T, Wilkinson JE, Zaslavsky A, Li 
H, Maher CA, Daignault-Newton S, Healy PN, et al. 
Transcription factors OVOL1 and OVOL2 induce the 
mesenchymal to epithelial transition in human cancer. PloS 
one. 2013; 8: e76773.
Oncotarget67608www.impactjournals.com/oncotarget
57. Jia D, Jolly MK, Boareto M, Parsana P, Mooney SM, Pienta 
KJ, Levine H, Ben-Jacob E. OVOL guides the epithelial-
hybrid-mesenchymal transition. Oncotarget. 2015; 6: 
15436-15448. doi: 10.18632/oncotarget.3623.
58. Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang 
J, Liu YN. EGF Receptor Promotes Prostate Cancer Bone 
Metastasis by Downregulating miR-1 and Activating 
TWIST1. Cancer Res. 2015; 75: 3077-3086.
59. Majid S, Dar AA, Saini S, Yamamura S, Hirata H, 
Tanaka Y, Deng G, Dahiya R. MicroRNA-205-directed 
transcriptional activation of tumor suppressor genes in 
prostate cancer. Cancer. 2010; 116: 5637-5649.
60. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, 
Colecchia M, Salvioni R, Supino R, Moretti R, Limonta 
P, Valdagni R, Daidone MG, Zaffaroni N. miR-205 Exerts 
tumor-suppressive functions in human prostate through 
down-regulation of protein kinase Cepsilon. Cancer Res. 
2009; 69: 2287-2295.
61. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, 
Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan 
BS, Giaccone G, Lowe SW, Takahashi N, et al. Loss of 
p63 and its microRNA-205 target results in enhanced cell 
migration and metastasis in prostate cancer. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2012; 109: 15312-15317.
62. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, 
Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R. 
Regulatory Role of mir-203 in Prostate Cancer Progression 
and Metastasis. Clinical cancer research : an official journal 
of the American Association for Cancer Research. 2011; 17: 
5287-5298.
63. Viticchie G, Lena AM, Latina A, Formosa A, Gregersen 
LH, Lund AH, Bernardini S, Mauriello A, Miano R, 
Spagnoli LG, Knight RA, Candi E, Melino G. MiR-203 
controls proliferation, migration and invasive potential of 
prostate cancer cell lines. Cell Cycle. 2011; 10: 1121-1131.
64. Shirakihara T, Kawasaki T, Fukagawa A, Semba K, Sakai 
R, Miyazono K, Miyazawa K, Saitoh M. Identification of 
integrin alpha3 as a molecular marker of cells undergoing 
epithelial-mesenchymal transition and of cancer cells with 
aggressive phenotypes. Cancer science. 2013; 104: 1189-
1197.
65. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, 
Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, 
Tanaka Y, Dahiya R. MicroRNA-145 is regulated by DNA 
methylation and p53 gene mutation in prostate cancer. 
Carcinogenesis. 2011; 32: 772-778.
66. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen 
S, Lai Y, Du H, Chen G, Liu G, Tang Y, Huang S, et al. 
Identification of miRs-143 and -145 that is associated with 
bone metastasis of prostate cancer and involved in the 
regulation of EMT. PloS one. 2011; 6: e20341.
67. Ren D, Wang M, Guo W, Huang S, Wang Z, Zhao X, Du H, 
Song L, Peng X. Double-negative feedback loop between 
ZEB2 and miR-145 regulates epithelial-mesenchymal 
transition and stem cell properties in prostate cancer cells. 
Cell and tissue research. 2014; 358: 763-778.
68. Guo W, Ren D, Chen X, Tu X, Huang S, Wang M, Song 
L, Zou X, Peng X. HEF1 promotes epithelial mesenchymal 
transition and bone invasion in prostate cancer under 
the regulation of microRNA-145. Journal of cellular 
biochemistry. 2013; 114: 1606-1615.
69. Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou 
X, Peng X. Wild-type p53 suppresses the epithelial-
mesenchymal transition and stemness in PC-3 prostate 
cancer cells by modulating miR145. International journal 
of oncology. 2013; 42: 1473-1481.
70. Qin W, Pan Y, Zheng X, Li D, Bu J, Xu C, Tang J, Cui R, 
Lin P, Yu X. MicroRNA-124 regulates TGF-alpha-induced 
epithelial-mesenchymal transition in human prostate cancer 
cells. International journal of oncology. 2014; 45: 1225-
1231.
71. Zhao X, Wang Y, Deng R, Zhang H, Dou J, Yuan H, 
Hou G, Du Y, Chen Q, Yu J. miR186 suppresses prostate 
cancer progression by targeting Twist1. Oncotarget. 2016; 
7:33136-51. doi: 10.18632/oncotarget.8887.
72. Roush S, Slack FJ. The let-7 family of microRNAs. Trends 
in cell biology. 2008; 18: 505-516.
73. Viswanathan SR, Daley GQ. Lin28: A microRNA regulator 
with a macro role. Cell. 2010; 140: 445-449.
74. Viswanathan SR, Daley GQ, Gregory RI. Selective 
blockade of microRNA processing by Lin28. Science. 
2008; 320: 97-100.
75. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng 
TL, Toffanin S, O’Sullivan M, Lu J, Phillips LA, Lockhart 
VL, Shah SP, Tanwar PS, Mermel CH, et al. Lin28 
promotes transformation and is associated with advanced 
human malignancies. Nature genetics. 2009; 41: 843-848.
76. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 
and Oct4 identify a sub-population of stem cell-like cells in 
ovarian cancer. Oncogene. 2010; 29: 2153-2159.
77. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time 
expression profiling of microRNA precursors in human 
cancer cell lines. Nucleic acids research. 2005; 33: 5394-
5403.
78. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread 
deregulation of microRNA expression in human prostate 
cancer. Oncogene. 2008; 27: 1788-1793.
79. Boyerinas B, Park SM, Hau A, Murmann AE, Peter 
ME. The role of let-7 in cell differentiation and cancer. 
Endocrine-related cancer. 2010; 17: F19-36.
80. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi 
S, Sarkar FH. Epithelial to mesenchymal transition is 
mechanistically linked with stem cell signatures in prostate 
cancer cells. PloS one. 2010; 5: e12445.
81. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara 
K, Mori M. Clinical significance of high mobility group 
Oncotarget67609www.impactjournals.com/oncotarget
A2 in human gastric cancer and its relationship to let-7 
microRNA family. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 
2008; 14: 2334-2340.
82. Dong Q, Meng P, Wang T, Qin W, Wang F, Yuan J, Chen 
Z, Yang A, Wang H. MicroRNA let-7a inhibits proliferation 
of human prostate cancer cells in vitro and in vivo by 
targeting E2F2 and CCND2. PloS one. 2010; 5: e10147.
83. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, 
Moustakas A. HMGA2 and Smads co-regulate SNAIL1 
expression during induction of epithelial-to-mesenchymal 
transition. The Journal of biological chemistry. 2008; 283: 
33437-33446.
84. Lo UG, Yang D, Hsieh JT. The role of microRNAs in 
prostate cancer progression. Translational andrology and 
urology. 2013; 2: 228-241.
85. Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, 
Ju X, Meng X, Wang M, Zhang Z, Qin C, et al. miR-154 
inhibits EMT by targeting HMGA2 in prostate cancer cells. 
Molecular and cellular biochemistry. 2013; 379: 69-75.
86. Hermeking H. The miR-34 family in cancer and apoptosis. 
Cell death and differentiation. 2010; 17: 193-199.
87. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue 
W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, 
Chen C, et al. A microRNA component of the p53 tumour 
suppressor network. Nature. 2007; 447: 1130-1134.
88. Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, 
Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking 
H, Nikitin AY. miR-34 cooperates with p53 in suppression 
of prostate cancer by joint regulation of stem cell 
compartment. Cell reports. 2014; 6: 1000-1007.
89. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, 
Li X, Chen W, Wang J, Zhong X, Melamed J, Zhao J, Lee 
P. LEF1 Targeting EMT in Prostate Cancer Invasion Is 
Regulated by miR-34a. Molecular cancer research : MCR. 
2015; 13: 681-688.
90. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman 
MS, Chang I, Yamamura S, Tanaka Y, Chiyomaru T, Deng 
G, Dahiya R. miRNA-34b inhibits prostate cancer through 
demethylation, active chromatin modifications, and AKT 
pathways. Clinical cancer research : an official journal of 
the American Association for Cancer Research. 2013; 19: 
73-84.
91. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman 
MS, Chang I, Yamamura S, Tanaka Y, Deng G, Dahiya R. 
miR-23b represses proto-oncogene Src kinase and functions 
as methylation-silenced tumor suppressor with diagnostic 
and prognostic significance in prostate cancer. Cancer Res. 
2012; 72: 6435-6446.
92. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, 
deVere White RW, Kung HJ. miR-30 as a tumor suppressor 
connects EGF/Src signal to ERG and EMT. Oncogene. 
2014; 33: 2495-2503.
93. Wang M, Ren D, Guo W, Wang Z, Huang S, Du H, Song 
L, Peng X. Loss of miR-100 enhances migration, invasion, 
epithelial-mesenchymal transition and stemness properties 
in prostate cancer cells through targeting Argonaute 2. 
International journal of oncology. 2014; 45: 362-372.
94. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. 
miRNA-29b suppresses prostate cancer metastasis by 
regulating epithelial-mesenchymal transition signaling. 
Molecular cancer therapeutics. 2012; 11: 1166-1173.
95. Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-
29b that represses Mcl-1, collagens, and matrix-
metalloproteinase-2 in prostate cancer cells. Genes & 
cancer. 2010; 1: 381-387.
96. Yan B, Guo Q, Nan XX, Wang Z, Yin Z, Yi L, Wei YB, 
Gao YL, Zhou KQ, Yang JR. Micro-ribonucleic acid 
29b inhibits cell proliferation and invasion and enhances 
cell apoptosis and chemotherapy effects of cisplatin via 
targeting of DNMT3b and AKT3 in prostate cancer. 
OncoTargets and therapy. 2015; 8: 557-565.
97. Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, 
Chen YR, Yang SB, Wu YD, Zeng YR, Qin GQ, Liang 
YX, Dai QS, et al. miR-195 Inhibits Tumor Progression by 
Targeting RPS6KB1 in Human Prostate Cancer. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2015; 21: 4922-4934.
98. Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu 
K, Tao T, Zhang X, Huang Y. miR-195 Inhibits EMT by 
Targeting FGF2 in Prostate Cancer Cells. PloS one. 2015; 
10: e0144073.
99. Zhang X, Tao T, Liu C, Guan H, Huang Y, Xu B, Chen 
M. Downregulation of miR-195 promotes prostate cancer 
progression by targeting HMGA1. Oncology reports. 2016.
100. Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato 
M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, 
Ichikawa T, Seki N. Tumor-suppressive microRNA-223 
inhibits cancer cell migration and invasion by targeting 
ITGA3/ITGB1 signaling in prostate cancer. Cancer science. 
2016; 107: 84-94.
101. Yang J, Hou Y, Zhou M, Wen S, Zhou J, Xu L, Tang X, Du 
YE, Hu P, Liu M. Twist induces epithelial-mesenchymal 
transition and cell motility in breast cancer via ITGB1-
FAK/ILK signaling axis and its associated downstream 
network. The international journal of biochemistry & cell 
biology. 2016; 71: 62-71.
102. Wang L, Song G, Tan W, Qi M, Zhang L, Chan J, Yu J, Han 
J, Han B. MiR-573 inhibits prostate cancer metastasis by 
regulating epithelial-mesenchymal transition. Oncotarget. 
2015; 6:35978-90. doi: 10.18632/oncotarget.5427.
103. Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, 
Dang TD, Wang F, Rowley DR. FGFR1 is essential for 
prostate cancer progression and metastasis. Cancer Res. 
2013; 73: 3716-3724.
104. Nam RK, Benatar T, Wallis CJ, Amemiya Y, Yang W, 
Oncotarget67610www.impactjournals.com/oncotarget
Garbens A, Naeim M, Sherman C, Sugar L, Seth A. MiR-
301a regulates E-cadherin expression and is predictive of 
prostate cancer recurrence. The Prostate. 2016.
105. Wen YC, Lee WJ, Tan P, Yang SF, Hsiao M, Lee LM, 
Chien MH. By inhibiting snail signaling and miR-23a-3p, 
osthole suppresses the EMT-mediated metastatic ability in 
prostate cancer. Oncotarget. 2015; 6: 21120-21136. doi: 
10.18632/oncotarget.4229.
106. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, 
Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt 
RL, Yanaihara N, Lanza G, et al. A microRNA expression 
signature of human solid tumors defines cancer gene targets. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2006; 103: 2257-2261.
107. Hatley ME, Patrick DM, Garcia MR, Richardson JA, 
Bassel-Duby R, van Rooij E, Olson EN. Modulation of 
K-Ras-dependent lung tumorigenesis by MicroRNA-21. 
Cancer cell. 2010; 18: 282-293.
108. Coppola V, Musumeci M, Patrizii M, Cannistraci A, 
Addario A, Maugeri-Sacca M, Biffoni M, Francescangeli 
F, Cordenonsi M, Piccolo S, Memeo L, Pagliuca A, Muto 
G, et al. BTG2 loss and miR-21 upregulation contribute 
to prostate cell transformation by inducing luminal 
markers expression and epithelial-mesenchymal transition. 
Oncogene. 2013; 32: 1843-1853.
109. Winkler GS. The mammalian anti-proliferative BTG/Tob 
protein family. Journal of cellular physiology. 2010; 222: 
66-72.
110. Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, 
Francescangeli F, Pecci R, Muto G, Collura D, Bedini R, 
Zeuner A, Valtieri M, Sentinelli S, et al. A microRNA code 
for prostate cancer metastasis. Oncogene. 2016; 35: 1180-
1192.
111. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu 
B, Janne OA, Seppala J, Lahdesmaki H, Tammela TL, 
Visakorpi T. Androgen-regulated miR-32 targets BTG2 
and is overexpressed in castration-resistant prostate cancer. 
Oncogene. 2012; 31: 4460-4471.
112. Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga 
CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, 
Chung LW. miR-154* and miR-379 in the DLK1-DIO3 
microRNA mega-cluster regulate epithelial to mesenchymal 
transition and bone metastasis of prostate cancer. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2014; 20: 6559-6569.
113. Edlund S, Bu S, Schuster N, Aspenstrom P, Heuchel 
R, Heldin NE, ten Dijke P, Heldin CH, Landstrom M. 
Transforming growth factor-beta1 (TGF-beta)-induced 
apoptosis of prostate cancer cells involves Smad7-
dependent activation of p38 by TGF-beta-activated kinase 
1 and mitogen-activated protein kinase kinase 3. Molecular 
biology of the cell. 2003; 14: 529-544.
114. Fujii T, Shimada K, Tatsumi Y, Tanaka N, Fujimoto K, 
Konishi N. Syndecan-1 up-regulates microRNA-331-3p and 
mediates epithelial-to-mesenchymal transition in prostate 
cancer. Molecular carcinogenesis. 2015.
115. Bijnsdorp IV, Hodzic J, Lagerweij T, Westerman B, 
Krijgsman O, Broeke J, Verweij F, Nilsson RJ, Rozendaal 
L, van Beusechem VW, van Moorselaar JA, Wurdinger 
T, Geldof AA. miR-129-3p controls centrosome number 
in metastatic prostate cancer cells by repressing CP110. 
Oncotarget. 2016; 7: 16676-16687. doi: 10.18632/
oncotarget.7572.
116. Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, 
Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, 
Li Q, et al. miR-409-3p/-5p promotes tumorigenesis, 
epithelial-to-mesenchymal transition, and bone metastasis 
of human prostate cancer. Clinical cancer research : an 
official journal of the American Association for Cancer 
Research. 2014; 20: 4636-4646.
117. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, 
Schneider-Broussard R, Jeter C. Prostate cancer stem/
progenitor cells: identification, characterization, and 
implications. Mol Carcinog. 2007; 46: 1-14.
118. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 
Prospective identification of tumorigenic prostate cancer 
stem cells. Cancer Res. 2005; 65: 10946-10951.
119. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. 
PC3 human prostate carcinoma cell holoclones contain 
self-renewing tumor-initiating cells. Cancer Res. 2008; 68: 
1820-1825.
120. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, 
Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool 
K, Coghlan L, Tang DG. Highly purified CD44+ prostate 
cancer cells from xenograft human tumors are enriched in 
tumorigenic and metastatic progenitor cells. Oncogene. 
2006; 25: 1696-1708.
121. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou 
J, Claypool K, Tang DG. Side population is enriched in 
tumorigenic, stem-like cancer cells, whereas ABCG2+ and 
ABCG2- cancer cells are similarly tumorigenic. Cancer 
Res. 2005; 65: 6207-6219.
122. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, 
Tang DG. Hierarchical organization of prostate cancer 
cells in xenograft tumors: the CD44+alpha2beta1+ cell 
population is enriched in tumor-initiating cells. Cancer Res. 
2007; 67: 6796-6805.
123. Fang YX, Chang YL, Gao WQ. MicroRNAs targeting 
prostate cancer stem cells. Exp Biol Med (Maywood). 2015; 
240: 1071-1078.
124. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee 
S, Padhye S, Sarkar FH. Hypoxia induced aggressiveness of 
prostate cancer cells is linked with deregulated expression 
of VEGF, IL-6 and miRNAs that are attenuated by CDF. 
PloS one. 2012; 7: e43726.
125. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun 
L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, 
Oncotarget67611www.impactjournals.com/oncotarget
Chitale D, et al. Loss of let-7 up-regulates EZH2 in prostate 
cancer consistent with the acquisition of cancer stem cell 
signatures that are attenuated by BR-DIM. PloS one. 2012; 
7: e33729.
126. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li 
H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, 
Bader AG, Fagin R, et al. The microRNA miR-34a inhibits 
prostate cancer stem cells and metastasis by directly 
repressing CD44. Nat Med. 2011; 17: 211-215.
127. Liu C, Tang DG. MicroRNA regulation of cancer stem 
cells. Cancer Res. 2011; 71: 5950-5954.
128. Wicha MS. Stemming a tumor with a little miR. Nat Med. 
2011; 17: 162-164.
129. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, 
Chang I, Zaman MS, Deng G, Tanaka Y, Dahiya R. 
miRNA-708 control of CD44(+) prostate cancer-initiating 
cells. Cancer Res. 2012; 72: 3618-3630.
